NewsBenzingaReported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Benzinga 2026.10.26 06:42 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Equal-Weight on W.W. Grainger, Raises Price Target to $1590 SpaceX's IPO Playbook Could Give Anthropic A $19B Buying Cushion—But There's A Catch What Is Going on With CoreWeave Stock on Monday? Morgan Stanley Maintains Underweight on Virgin Galactic Holdings, Lowers Price Target to $1.75 Occidental Petroleum Analyst Turns Bearish Due To Limited Volume Upside If You Invested $1000 In Monster Beverage Stock 5 Years Ago, You Would Have This Much Today